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TISSUE ENGINEERED BONE GRAFT SUBSTITUTE 
 
*Sylvester, S; *Norman, TL; +*Mukherjee, N 
*West Virginia University, Morgantown, WV 
 
Introduction: Tissue engineering products are recognized for their 
potential as treatment alternatives for repairing/regenerating tissue lost 
due to trauma or degeneration, or to correct congenital malformations. 
The goal is to restore organ function (1). Our tissue engineering strategy 
to generate bone follows the paradigm of implanting osteogenic cells in 
a scaffold material that will temporarily support the cells until they can 
form bone. In this study we isolated cells from bone marrow of New 
Zealand white rabbits and tested their osteogenic potential in various 
culture conditions. We then embedded these cells in a commercially 
available mineralized collagen matrix (Healos from Orquest, Mountain 
View, Ca) and assessed the ability of these cells to populate the matrix 
and form bone like tissue in vitro. The overall goal of this research is to 
develop alternatives to autologous bone graft substitutes for procedures 
such as posterolateral spinal fusion. If successful, the findings may 
eventually lead to enhanced healing and reduce morbidity associated 
with autologous bone grafting.  
 
Methods: Bone marrow was isolated from adult male New Zealand 
white rabbit femurs. They were expanded in monolayer culture adapted 
from standard protocols developed for rat models (2) (3).  The fastest 
growing cells were selected for further experiments.    
Well-plate: Approximately 5x104 cells were placed in each 
treatment well of a 24 well plate and exposed to one of three treatments: 
Minimum essential medium (MEM), 40ng/mL Dexamethasone and 
MEM or 50ng/mL BMP-2, 40ng/mL Dexamethasone and MEM.  The 
non-control treatments were given additional mineralizing agents of 
2.8x10-4M concentration of L-ascorbic acid and 10mM concentration of 
b-glycerophosphate starting on day 7 and every media change thereafter 
(4) (5).  The media was changed every three days. 
Wells were stained with alkaline phosphatase staining kit 
(Sigma, St. Louis, MO) to determine the activity of the alkaline 
phosphatase enzyme, an early indicator of osteogenesis (6) and von 
Kossa (7), which indicates mineralization, a late stage of osteogenesis  
 Healos: Healos matrix was cut into 4mm squares and placed 
into sterile 24 well plates.  2.5x106 bone marrow derived cells suspended 
in 0.2ml of MEM media were added to the Healos mesh. After allowing 
2 hours for the cells to attach, culture media was added. 40ng/ml 
Dexamethasone was used as an osteoinductive agent (8).  The different 
groups were: Healos matrix alone and Healos matrix + cells. Media was 
changed every 3 days.  After 1 and 2 weeks in culture, the constructs 
were fixed in 10% neutral buffered formalin, processed for histology and 
stained with Hematoxylin and Eosin (H&E) and Von Kossa. 
 
Essential Results:   
Well-plate:  ANOVA analysis showed that some groups were 
significantly different from others [F=0.0023 at p=0.05 level] in terms of 
alkaline phosphatase activity.  The trend in the data showed that alkaline 
phosphatase activity increased over a three-week period with a decline 
in activity seen at week 4 (Figure 1). Von Kossa staining was not 
observed at week 1 – 3 sampling time points.  Week 4 showed a positive 
stain for Von Kossa (Figure 2) with the MEM+BMP-2+Dexa treatment 
having the largest percent area coverage [p=0.001].   
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Fig 1:  Alkaline Phosphatase enzyme activity increased through day 21 
and declined later [F=0.002 at p=0.05 level]. 
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Fig 2:  Von Kossa staining was not observed through day 21 but 
appeared at day 28.  Treatment groups showed significantly higher 
mineralization than controls on day 28 [p=0.001] 
 
Healos: The cells appeared to survive in the Healos mesh. 
The media changed color signifying that the cells were metabolically 
active. Some cells seemed to migrate from the mesh and populated the 
bottom of the dish. The H &E staining showed that at two weeks, many 
cells attached to the mesh and were able to deposit extra-cellular matrix 
around them. The Von Kossa staining showed that the matrix had not yet 
mineralized at 2 weeks, as expected (Figure 3a,b).  
 
             
Fig 3: After 2 weeks in culture, the rabbit bone marrow derived cells 
(nuclei stained blue, indicated by arrows) populated the matrix, which 
stained pink, indicated by arrow heads (A). The cells are able to lay 
down matrix around them (faint pink). B) Under Von Kossa staining, the 
Healos matrix stains black while the extracellular matrix deposited by 
the cells is apparent but not mineralized.                
 
Discussion: This work showed that we were able to isolate precursor 
cells from bone marrow that could be induced to differentiate down the 
osteogenic pathway in vitro, as shown by alkaline phosphatase activity 
and von Kossa staining. These cells were able to populate the healos 
mesh and lay down extracellular matrix around them. Since the Healos 
is bovine collagen coated with hydroxyapatite, it also stained positive for 
Von Kossa and it will be hard to tell if the cells deposited mineralized 
matrix at time points greater than 2 weeks. These results have 
encouraged us to use this tissue engineering construct as a bone graft 
substitute in a rabbit posterolateral spinal fusion model. 
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